Antibodies Directed to the Unprocessed Receptor Tyrosine Kinase c-Met
AssigneesLudwig Institute for Cancer Research, Monash University
InventorsTerrance Grant Johns, Ermanno Gherardi, Andrew Mark Scott
Life of this patent
Estimating the term…
Abstract
The present invention relates to antibodies that specifically bind to unprocessed c-Met present on the surface of tumor cells. These antibodies are useful in the diagnosis and treatment of cancer or as agents for delivering moieties to cancer cells. The antibodies of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents.
Claims18
1-47. (canceled)
An isolated antibody or antigen-binding fragment thereof that specifically binds to unprocessed c-Met present on the surface of a tumor cell.
A vaccine antigen comprising the sequence VVDTYYDDQL (SEQ ID NO:2), RHFQSCSQCLSAPPFVQCGW (SEQ ID NO:5) or RHFQSCSQCLSAPPF (SEQ ID NO:6), together with a pharmaceutically acceptable carrier or excipient.
A method of immunizing an animal to obtain an anti-c-Met antibody, comprising administering to the animal a truncated c-Met antigen fragment comprising the sequence of SEQ ID NO:1, in sequence with or together with cells over-expressing c-Met.
Dependencies are inferred from the claim text.